|
pharmacy and pharmacology environmental studies |
9 |
|
toxicology and environmental safety |
9 |
|
biology |
7 |
|
endothelium |
6 |
|
pulmonary delivery |
5 |
|
animals |
4 |
|
biological factors - pharmacology |
4 |
|
cardiovascular disease |
4 |
|
coronary vessels - drug effects - metabolism - physiology |
4 |
|
coronary vessels - drug effects - physiology |
4 |
|
cyclic gmp - biosynthesis |
4 |
|
dose-response relationship, drug |
4 |
|
endothelial dysfunction |
4 |
|
endothelial nitric oxide synthase |
4 |
|
endothelium, vascular - drug effects - metabolism - physiology |
4 |
|
endothelium-dependent relaxing factors - pharmacology |
4 |
|
endothelium-derived hyperpolarizing factor |
4 |
|
enos |
4 |
|
enzyme inhibitors - pharmacology |
4 |
|
epidermal growth factor receptor transactivation |
4 |
|
g protein activation |
4 |
|
genistein |
4 |
|
gi/o protein |
4 |
|
gtp-binding protein alpha subunits, gi-go - metabolism |
4 |
|
guanylate cyclase - antagonists & inhibitors |
4 |
|
hypertension |
4 |
|
hypoxia |
4 |
|
inhalation |
4 |
|
ion channel gating - drug effects |
4 |
|
large-conductance calcium-activated potassium channels - antagonists & inhibitors |
4 |
|
membrane estrogen receptor |
4 |
|
muscle relaxation - drug effects |
4 |
|
muscle, smooth, vascular - drug effects - metabolism - physiology |
4 |
|
natriuretic peptides - pharmacology - physiology |
4 |
|
nitric oxide |
4 |
|
nitric oxide - metabolism - pharmacology - physiology |
4 |
|
nitric oxide donors - pharmacology |
4 |
|
oxadiazoles - pharmacology |
4 |
|
oxazines - pharmacology |
4 |
|
patch-clamp techniques |
4 |
|
peptides - pharmacology |
4 |
|
pertussis toxin |
4 |
|
pig coronary artery |
4 |
|
reactive oxygen species |
4 |
|
rna interference |
4 |
|
soluble guanylyl cyclase |
4 |
|
swine |
4 |
|
vasodilation - drug effects - physiology |
4 |
|
17β-estradiol |
3 |
|
17β-oestradiol |
3 |
|
3′-5′-cyclic adenosine monophosphate (cyclic amp) |
3 |
|
acetylcholine - pharmacology |
3 |
|
adult |
3 |
|
aging |
3 |
|
ang ii type 1 receptors |
3 |
|
angiotensin ii |
3 |
|
aspirin |
3 |
|
atherosclerosis |
3 |
|
blood coagulation |
3 |
|
blood loss |
3 |
|
bronchial epithelial cells |
3 |
|
calcium |
3 |
|
cardiovascular diseases |
3 |
|
cgmp-dependent protein kinase |
3 |
|
chemical parameter |
3 |
|
coronary artery, porcine |
3 |
|
coronary heart disease |
3 |
|
coronary vessels - drug effects - enzymology - physiology |
3 |
|
cyclic adenosine monophosphate |
3 |
|
cyclic gmp-dependent protein kinases - chemistry - physiology |
3 |
|
cyclic nucleotides |
3 |
|
deamino arginine vasopressin - pharmacology |
3 |
|
desmopressin |
3 |
|
disulfide bonds |
3 |
|
endothelium-derived contracting factor |
3 |
|
endothelium-derived hyperpolarization |
3 |
|
estrogen receptor beta |
3 |
|
flavonoid |
3 |
|
flavonoids |
3 |
|
glucocorticoid receptor |
3 |
|
guanylate cyclase - chemistry - physiology |
3 |
|
hemostasis - drug effects |
3 |
|
hormone replacement therapy |
3 |
|
hyperlipidemia |
3 |
|
hypothermia |
3 |
|
hypothermia - blood |
3 |
|
inflammation |
3 |
|
lipopolysaccharide |
3 |
|
medical sciences |
3 |
|
microrna (mirna) |
3 |
|
non-genomic |
3 |
|
notoginsenoside ft1 |
3 |
|
panax notoginseng |
3 |
|
peroxisome proliferator-activated receptor agonist |
3 |
|
porcine coronary artery |
3 |
|
prostaglandin |
3 |
|
puerarin |
3 |
|
radix puerariae |
3 |
|
receptor-mediated contraction |
3 |
|
receptors, cytoplasmic and nuclear - chemistry - physiology |
3 |
|
relaxation activity |
3 |
|
respiratory diseases |
3 |
|
short hairpin rna (shrna) |
3 |
|
short interfering rna (sirna) |
3 |
|
small-conductance calcium-activated potassium channel |
3 |
|
sodium–potassium atpase |
3 |
|
structure-activity relationship |
3 |
|
vascular reactivity |
3 |
|
vascular relaxation |
3 |
|
vasoconstriction |
3 |
|
vasodilatation |
3 |
|
vasodilation |
3 |
|
15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid - pharmacology |
2 |
|
3′,5′‐cyclic inosine monophosphate |
2 |
|
5-hydroxytryptamine |
2 |
|
5/6 nephrectomy |
2 |
|
acetylcholine |
2 |
|
adenosine monophosphate‐activated protein kinase |
2 |
|
ageing |
2 |
|
anoxia - physiopathology |
2 |
|
antihypertensive agents - pharmacology |
2 |
|
antioxidant |
2 |
|
antioxidants - pharmacology |
2 |
|
aorta, thoracic - drug effects - physiology |
2 |
|
biased soluble guanylyl cyclase (sgc) activity |
2 |
|
blood pressure |
2 |
|
blood pressure - drug effects |
2 |
|
calcimycin - pharmacology |
2 |
|
calcium channel antagonist |
2 |
|
calcium-independent phospholipase a2 |
2 |
|
cancer therapy |
2 |
|
cardiac output |
2 |
|
cardiovascular diseases - metabolism |
2 |
|
cardiovascular system - metabolism |
2 |
|
chinese medicine |
2 |
|
cimp |
2 |
|
conductance |
2 |
|
coronary |
2 |
|
coronary vessels - drug effects |
2 |
|
covid-19 |
2 |
|
cromakalim - pharmacology |
2 |
|
cyclic imp |
2 |
|
cyclooxygenases |
2 |
|
danshen extract |
2 |
|
diabetes |
2 |
|
diethylstilbestrol |
2 |
|
drug synergism |
2 |
|
drugs, chinese herbal - pharmacology |
2 |
|
endothelial cells |
2 |
|
endothelin-1 |
2 |
|
endothelium, vascular |
2 |
|
endothelium, vascular - drug effects |
2 |
|
endothelium, vascular - physiology |
2 |
|
endothelium-dependent hyperpolarization |
2 |
|
endothelium-dependent relaxation |
2 |
|
endothelium-derived relaxing factor |
2 |
|
endothelium‐dependent hyperpolarization |
2 |
|
endothelium‐dependent vasoconstriction |
2 |
|
estradiol |
2 |
|
estradiol - analogs & derivatives - pharmacology |
2 |
|
estradiol - pharmacology |
2 |
|
estrogen antagonists - pharmacology |
2 |
|
estrogens |
2 |
|
estrogens - metabolism |
2 |
|
estrone |
2 |
|
eta receptors |
2 |
|
female |
2 |
|
gender |
2 |
|
gene silencing |
2 |
|
glomerular endothelial cell |
2 |
|
heart rate - drug effects |
2 |
|
high pressure liquid chromatography |
2 |
|
human umbilical arteries |
2 |
|
humans |
2 |
|
hydrogen peroxide |
2 |
|
hydroquinone |
2 |
|
hypoxic augmentation |
2 |
|
hypoxic vasoconstriction |
2 |
|
ifn-gamma |
2 |
|
inosine 3′, 5′-cyclic monophosphate |
2 |
|
inosine 3′,5′-cyclic monophosphate |
2 |
|
intermediate-conductance calcium-activated potassium channels |
2 |
|
intranasal delivery |
2 |
|
ionophores - pharmacology |
2 |
|
jnk |
2 |
|
kaempferol |
2 |
|
kaempferols - pharmacology |
2 |
|
l-arginine |
2 |
|
lysophosphatidylcholine |
2 |
|
magnesium - pharmacology |
2 |
|
magnesium ions |
2 |
|
magnesium tanshinoate b |
2 |
|
magnesium tanshinoate b (mtb) |
2 |
|
major histocompatibility complex |
2 |
|
male |
2 |
|
mesenteric blood flow |
2 |
|
mhc class ii transactivator |
2 |
|
microcirculation |
2 |
|
microrna |
2 |
|
muscle relaxation |
2 |
|
muscle relaxation - physiology |
2 |
|
muscle, smooth, vascular - drug effects - physiology |
2 |
|
muscle, smooth, vascular - drug effects - physiopathology |
2 |
|
muscle, smooth, vascular - physiology |
2 |
|
nad(p)h:quinone oxidoreductase 1 |
2 |
|
nad(p)h:quinone oxidoreductase 1 (nqo-1) |
2 |
|
neutralising antibody, pulmonary delivery |
2 |
|
nitrate/nitrite |
2 |
|
nitric oxide potassium channels |
2 |
|
nitric oxide synthase |
2 |
|
nitroprusside - pharmacology |
2 |
|
no |
2 |
|
non-nucleoside reverse transcriptase inhibitors |
2 |
|
oncology medical sciences |
2 |
|
peroxisome proliferator-activated receptor-α agonists |
2 |
|
phenanthrolines - pharmacology |
2 |
|
phosphatidylcholine |
2 |
|
physiology medical sciences |
2 |
|
platelet-activating factor |
2 |
|
potassium channel opener |
2 |
|
potassium channels |
2 |
|
prostacyclin synthase |
2 |
|
prostaglandin e2 |
2 |
|
prostanoids |
2 |
|
protease inhibitors |
2 |
|
quinones |
2 |
|
rat aorta |
2 |
|
rat mesenteric arteries |
2 |
|
rats |
2 |
|
rats, sprague-dawley |
2 |
|
receptors, estrogen - metabolism |
2 |
|
receptors, nicotinic - metabolism |
2 |
|
relaxation |
2 |
|
renal blood flow |
2 |
|
renal function |
2 |
|
resistance arteries |
2 |
|
respiratory viral infections |
2 |
|
rho kinase |
2 |
|
s-nitrosothiols |
2 |
|
salvia miltiorrhiza |
2 |
|
salvia miltiorrhiza - chemistry |
2 |
|
small interfering rna |
2 |
|
small-conductance calcium-activated potassium channels |
2 |
|
smooth muscle |
2 |
|
sphingomyelin |
2 |
|
spray drying |
2 |
|
streptozotocin induced |
2 |
|
subcutaneous artery |
2 |
|
tail artery |
2 |
|
tamoxifen - pharmacology |
2 |
|
testosterone |
2 |
|
thromboxane a2 |
2 |
|
time factors |
2 |
|
umbilical arteries - drug effects - physiopathology |
2 |
|
umbilical cord closure |
2 |
|
vascular function |
2 |
|
vascular smooth muscle |
2 |
|
vasoconstrictor agents - pharmacology |
2 |
|
vasodilation - drug effects |
2 |
|
vasodilation - physiology |
2 |
|
vasodilator agents - pharmacology |
2 |
|
vessel |
2 |
|
1400w |
1 |
|
amidines - pharmacology |
1 |
|
angiogenesis |
1 |
|
angiotensin |
1 |
|
angiotensin ii - pharmacology |
1 |
|
antibody fragment |
1 |
|
arteries - drug effects - physiopathology |
1 |
|
asthma |
1 |
|
benzylamines - pharmacology |
1 |
|
blood flow |
1 |
|
capacitance |
1 |
|
cardiac output - drug effects |
1 |
|
cell crosstalk |
1 |
|
circulatory filling pressure |
1 |
|
consciousness |
1 |
|
cyclodextrin |
1 |
|
cyclooxygenase |
1 |
|
diabetes mellitus, experimental - physiopathology |
1 |
|
diabetic nephropathy |
1 |
|
endotoxemia - chemically induced - enzymology - physiopathology |
1 |
|
escherichia coli |
1 |
|
glomerular endothelial cells |
1 |
|
glomerular endothelial dysfunction |
1 |
|
hemodynamics - drug effects |
1 |
|
hypertension, pulmonary - drug therapy - metabolism - physiopathology |
1 |
|
immune checkpoints |
1 |
|
inducible nitric oxide synthase |
1 |
|
leucine |
1 |
|
lipopolysaccharides |
1 |
|
lung cancer |
1 |
|
mean |
1 |
|
mean arterial pressure |
1 |
|
microrna-590-3p |
1 |
|
monocrotaline |
1 |
|
ng-nitroarginine methyl ester - pharmacology |
1 |
|
nitric oxide - antagonists & inhibitors |
1 |
|
nitric oxide synthase - antagonists & inhibitors |
1 |
|
nitric oxide synthase inhibition |
1 |
|
nitric oxide synthase type ii |
1 |
|
nitroarginine - pharmacology |
1 |
|
noradrenaline |
1 |
|
norepinephrine - pharmacology |
1 |
|
ovariectomy |
1 |
|
peptide-based vectors |
1 |
|
phosphofructokinase/fructose bisphosphatase 3 |
1 |
|
pulmonary vascular resistance |
1 |
|
pyrrolizidine alkaloid |
1 |
|
regional blood flow - drug effects |
1 |
|
septic shock |
1 |
|
single cell rna analysis |
1 |
|
sirna delivery |
1 |
|
sphingosine 1-phosphate receptor 1 |
1 |
|
systemic vascular resistance |
1 |
|
total peripheral resistance |
1 |
|
vascular resistance - drug effects |
1 |
|
vasoconstriction - drug effects |
1 |
|
vasoconstriction - drug effects - physiology |
1 |
|
veins - drug effects - physiopathology |
1 |
